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Familial chylomicronaemia syndrome (FCS) is a rare, inherited disorder characterised by impaired
clearance of triglyceride (TG)-rich lipoproteins from plasma, leading to severe hypertriglyceridaemia
(HTG) and a markedly increased risk of acute pancreatitis. It is due to the lack of lipoprotein lipase (LPL)
function, resulting from recessive loss of function mutations in the genes coding LPL or its modulators. A
large overlap in the phenotype between FCS and multifactorial chylomicronaemia syndrome (MCS)
contributes to the inconsistency in how patients are diagnosed and managed worldwide, whereas the
incidence of acute hypertriglyceridaemic pancreatitis is more frequent in FCS. A panel of European ex-
perts provided guidance on the diagnostic strategy surrounding FCS and proposed an algorithm-based
diagnosis tool for identiﬁcation of these patients, which can be readily translated into practice. Fea-
tures included in this FCS score comprise: severe elevation of plasma TGs (fasting TG levels >10mmol/L
[885mg/dL] on multiple occasions), refractory to standard TG-lowering therapies, a young age at onset,
the lack of secondary factors (except for pregnancy and oral oestrogens) and a history of episodes of
acute pancreatitis. Considering 53 FCS patients from three cohorts and 52 MCS patients from three
cohorts, the overall sensitivity of the FCS score (10) was 88% (95% conﬁdence interval [CI]: 0.76, 0.97)
with an overall speciﬁcity of 85% (95% CI: 0.75, 0.94). Receiver operating characteristic curve area waslisme et Prevention Car-
e (ICAN), Ho^pital Pitie Sal-
France.
).
B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
P. Moulin et al. / Atherosclerosis 275 (2018) 265e2722660.91. Pragmatic clinical scoring, by standardising diagnosis, may help differentiate FCS from MCS, may
alleviate the need for systematic genotyping in patients with severe HTG and may help identify high-
priority candidates for genotyping.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1.1. Key issues in the identiﬁcation and diagnosis of familial
chylomicronaemia syndrome
Familial chylomicronaemia syndrome (FCS) is a rare, inherited
disorder of triglyceride (TG)-rich lipoprotein metabolism [1]. The
estimated worldwide prevalence is approximately one individual
per million [2]. It often presents in childhood and has been
described in all ethnicities, although a higher prevalence has been
observed in some geographical areas such as Quebec, due to a
founder effect [3].
Chylomicronaemia is the accumulation in the bloodstream of
chylomicrons, i.e., large, TG-rich lipoprotein particles produced by
enterocytes after a meal [1,2]. Under physiological conditions,
chylomicrons are rapidly cleared from plasma by the action of li-
poprotein lipase (LPL), an enzyme located on the endothelial sur-
face of adipose and muscle tissues, which hydrolyses TG into fatty
acids and glycerol. Chylomicrons are converted into chylo-
remnants, which are in turn taken up by speciﬁc cellular re-
ceptors [4]. In FCS, a lack of LPL functionality, mostly due to path-
ogenic variants in the set of genes involved in LPL function,
markedly impairs clearance of chylomicrons from the plasma. The
initial reports of FCS involved homozygous or compound hetero-
zygous carriers of loss of function mutations in LPL and apolipo-
protein C2 (APOC2) genes. Subsequently, combined loss of function
mutations in genes coding for apolipoprotein A5 (APOA5), lipase
maturation factor 1 (LMF1), glycosylphosphatidylinositol-anchored
high-density lipoprotein-binding protein 1 (GPIHBP1) and glycerol-
3-phosphate dehydrogenase 1 (G3PDH1) were also identiﬁed as
causal in FCS [1,5e11]. Additional genes are likely to be identiﬁed in
the future, since in a large proportion of patients (more than one-
third) with a phenotype similar to FCS, no deleterious variants in
the aforementioned genes can be identiﬁed [12,13].
Although environmental factors increase the magnitude of
hyperchylomicronaemia, they are not required for the expression of
FCS phenotype; however, many cases of FCS syndrome in women
are discovered at the third trimester of pregnancy. It has been
consistently reported that FCS strongly increases the risk of acute
pancreatitis (AP) [14]. However, it remains an elusive goal to
identify patients with FCS who will develop AP versus those who
will not.
A key concern is that a clear diagnosis might be missed in pa-
tients with FCS. Indeed, the condition is very rare and high levels of
TGs are more often due to multifactorial chylomicronaemia syn-
drome (MCS) [8,15]. This syndrome results from the combination,
in various proportions, of predisposing variants ranging from loss of
function heterozygous mutations to likely pathogenic variants in
candidate genes with co-morbidities known to raise plasma TGs
(uncontrolled diabetes, hypothyroidism, pregnancy) and environ-
mental factors (such as alcohol abuse, unhealthy diet) and certain
medications (such as glucocorticoids, ethinylestradiol, neurolep-
tics). MCS is also characterised by an increased risk of AP but the
estimated odds ratio of 50 is clearly less than the AP odds ratio of
360 reported in patients with FCS (Fig. 1) [16,17].
The apparently similar phenotype of MCS means that FCS maybe missed or undiagnosed. Many patients with FCS suffer recurrent
episodes of AP before the diagnosis is made. Lack of disease
awareness on the part of physicians in emergency medicine, pri-
mary care and gastroenterology is a key barrier to FCS diagnosis,
leading to a low rate of appropriate referrals and follow-up.
A panel of European clinical experts experienced in diagnosing
FCS convened in Amsterdam in July 2017 to discuss the deﬁnition
and terminology of FCS and optimal strategies for the identiﬁcation,
diagnosis and evaluation of patients, which could be readily
translated into practice to improve the approach used to identify
and diagnose FCS, which we present below.2. Challenges in deﬁning FCS
 FCS is characterised by very high plasma TG concentrations
(>10mmol/L or 885mg/dL in the untreated state). A key char-
acteristic is milky looking plasma, whereby awhite chylomicron
layer ﬂoats above the lactescent plasma compartment following
decantation and/or low-speed centrifugation of the plasma
sample. Although controversial [2], the expert panel considered
that most adult patients with FCS present with both increased
chylomicrons and very low-density lipoproteins (VLDLs), and,
consequently, more often display type V than type I dyslipi-
daemia [9,18,19]. Therefore, type I phenotype has been consid-
ered to be poorly sensitive but a highly speciﬁc feature of FCS in
adults. Type I phenotype is more frequently found in children
with FCS, which may reﬂect the ability of hepatic lipase to
efﬁciently hydrolyse VLDL-TG in children and teenagers [20]. It
is noteworthy that few patients with auto-immune hyper-
chylomicronaemia also present with type I phenotype [5,21].
 Patients with FCS may experience physical complications
including abdominal pain, which can range in intensity from
mild to incapacitating [1]. Moreover, they have a high risk of
developing severe recurrent AP [22,23], a potentially life-
threatening complication [24], resulting in increased
morbidity and mortality [2,25], and may lead to chronic
pancreatitis, permanent damage to pancreatic tissue, pancreatic
insufﬁciency and type 3 diabetes [26,27]. Studies have high-
lighted a signiﬁcant relationship between TG level and pancre-
atitis, with a 4% increased risk of AP for every 100mg/dL or
~1.1mmol/L increase in TG level [28,29]. In a prospective cohort
study, even mild hypertriglyceridaemia (HTG) (non-fasting
TG> 177mg/dL [2mmol/L]) was associated with a graded
increased risk of AP [30].
 Other clinical symptoms include transient eruptive xanthomas,
which affect <50% of individuals with FCS, often appearing on
the trunk and extremities, and lipemia retinalis, a milky
appearance of the retinal vessels [1,29]. Hepatosplenomegaly
may also result from TG uptake by macrophages [1]. Neurolog-
ical symptoms, such as irritability, memory problems, dementia
and depression, have also been documented [24]. Patients with
FCS tend to have a lower body weight because of restriction of
their food intake owing to abdominal pain. The impact of the
disease is such that quality of life and daily activities including
work may be adversely affected [31,32].
Acute
pancreatitis +
Acute
pancreatitis -
FCS
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Fig. 1. Relative prevalence of pancreatitis in FCS and MCS.
Since the prevalence of MCS is much higher than FCS, although hypertriglyceridaemic acute pancreatitis relative risk is much less in MCS, the contribution of FCS and MCS to the
overall incidence of pancreatitis cases is likely to be similar. FCS, familial chylomicronaemia syndrome; MCS, multifactorial chylomicronaemia syndrome.
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A   Homozygous coding mutation, LPL
B   Homozygous coding mutation,
      APOC2, APOA5, GPIHBP1, LMF1
C   Composite heterozygous coding mutation,
  LPL, APOC2, APOA5, GPIHBP1, LMF1
Syndromic hyperchylomicronaemia
PLIN, lamin, PPARG
D   Composite heterozygous coding mutation +
      susceptibility variants,
 LPL, APOC2, APOA5, GPIHBP1, LMF1
E   Combination of variants/genetic load,
LPL, APOC2, APOA5, GPIHBP1, LMF1,
      APOE, APOC3...
F   Sporadic hyperchylomicronaemia
      One or no minor functional variant
Fig. 2. Genetic load in FCS versus MCS.
FCS, familial chylomicronaemia syndrome; MCS, multifactorial chylomicronaemia
syndrome; LPL, lipoprotein lipase; APOC2, apolipoprotein C2; APOA5, apolipoprotein
A5; GPIHBP1, glycosylphosphatidylinositol-anchored high-density lipoprotein-binding
protein 1; LMF1, lipase maturation factor 1; APOE, apolipoprotein E; APOC3, apolipo-
protein C3; PPARG, peroxisome proliferator-activated receptor gamma.
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well-deﬁned terminology when describing the condition, ensuring
that this is something that will be easily identiﬁed by patients,
clinical chemists and primary care physicians, in addition to spe-
cialists more familiar with the area. Of the numerous terms that
have been used historically in the literature, in the clinical setting
and by patient societies, use of “FCS” seems to be a pragmatic
choice. Indeed, there are key patient organisations that are using
this terminology, including the LPLD Alliance (http://www.
lpldalliance.org/) in the UK and The FCS Foundation (https://
www.livingwithfcs.org/) in the USA. The condition should be
characterised as a ‘syndrome’ due to the variety of symptoms
present, with different presentations between individuals. The
main limitation is that most of the cases are apparently sporadic,
within a nuclear family, due to the recessive character of the dis-
ease. However, the preferred terminology is “familial chylomicro-
naemia syndrome” e abbreviated as “FCS”.
3. Diagnosis
3.1. Disease classiﬁcation
One of the main difﬁculties that we considered is the uncertain
boundary between FCS and MCS, since the genetic load increases
progressively fromMCS, where it can beminimal, to FCS, where it is
maximal in carriers of homozygous nonsense mutations in the LPL
gene. The full spectrum is described in Fig. 2. We propose that FCS
corresponds to a monogenic disorder with a genetic load high
enough to generate constant HTG, mostly >10mmol/L (885mg/dL)
with recurrent decompensations in the absence of obvious sec-
ondary factors (and decreased post-heparin LPL activity, although
infrequently assayed in clinical practice). In addition to homozy-
gous LPL deﬁciency, homozygous loss of function mutations in
APOC2, APOA5, GPIHBP1, LMF1 and G3PDH1 genes should be
considered, as well as compound heterozygous mutations
involving LPL and these genes.
Patients with MCS may have a combination of a heterozygous
loss of functionmutation and/or likely pathogenic frequent variants
in TG-raising genes, thus producing (oligogenic/polygenic) severe
HTG [8,9]. However, in such cases, hyperchylomicronaemia is often
transient and low LPL activity is inconstant. Between recurrent
decompensations, these patients mostly present with mild HTG.
This phenotype is often observed in heterozygous APOA5 loss of
function mutations combined with various combinations of vari-
ants such as Haplotype Apo AV*2 and Apo AV*3 [33e35]. Betweendecompensations, whereas plasma TG levels have partially
decreased, post-heparin LPL activity is found to be normal 10min
after injection but is decreased in many patients 60min after in-
jection. This ﬁnding supports the hypothesis that some patients
with MCS might have subtle alterations of LPL bioavailability [36].
Additionally, the apolipoprotein E2 allele is over-represented in
patients with MCS; it is likely that the E2 allele contributes to de-
creases in hepatic chylomicron remnant clearance in patients car-
rying additional pathogenic variants known to alter LPL activity
[15,37]. However, hyperchylomicronaemia is unusual even in E2/E2
patients, and they should be considered as suffering from MCS
rather than FCS.3.2. Pivotal features needed for an appropriate diagnosis of FCS
Differentiation of FCS fromMCS is difﬁcult, since the clinical and
biological phenotype might be similar on decompensations. A
number of parameters should be taken into consideration, given
Recruitment phase
Patient pre-selection in non-acute setting
Severe primary HTG (fasting TGs >10 mmol/L or 885 mg/dL)
1.  Fasting TGs >10 mmol/L for 3 consecutive 
     blood analyses (+5)a
     º  Fasting TGs >20 mmol/L at least once (+1)
2.  Previous TGs <2 mmol/L (-5)
3.  No secondary factorb (except pregnancyc and
     ethinylestradiol) (+2)
4.  History of pancreatitis (+1)
5.  Unexplained recurrent abdominal pain (+1)
6.  No history of familial combined 
     hyperlipidaemia (+1)
7.  No response (TG decrease <20%) to 
     hypolipidaemic treatment (+1)
8.  Onset of symptoms at age:
º  <40 years (+1)
º  <20 years (+2)
     º  <10 years (+3)
FCS score:
≥10: FCS very likely
≤9: FCS unlikely
≤8: FCS very unlikely
Fig. 3. A practical diagnostic scoring system for FCS.
Numbers in parentheses¼weighting given to the presence of each item. FCS
score¼ the sum of all items present. FCS, familial chylomicronaemia syndrome; HTG,
hypertriglyceridaemia; TG, triglyceride. a Plasma TG concentration measured at least
one month apart. Eruptive xanthoma may be used as a surrogate for high TG levels
(rare). b Secondary factors include alcohol, diabetes, metabolic syndrome, hypothy-
roidism, corticotherapy and additional drugs [6]. c If diagnosis is made during preg-
nancy, a second assessment is necessary to conﬁrm diagnosis post-partum.
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above is not commonly used in clinical practice, and that both FCS
and MCS share mostly the same type V lipid phenotype. Therefore,
TG levels over time, clinical signs and history must be all be
considered for establishing a diagnosis of FCS. Although arbitrary,
our proposed cut-off TG level for FCS diagnosis is fasting TG levels
>10mmol/L or 885mg/dL. This is supported by a study of Italian
patients with monogenic HTG, in which the lowest TG levels re-
ported were ~10mmol/L [12].
It is advisable to check for a chylomicron layer by keeping
plasma samples overnight when centrifugation is not able to pro-
vide evidence for a creamy layer. Screening for chylomicrons by
agarose gel electrophoresis (lipidogram) is not reliable, since the
largest chylomicrons often cannot enter the gel and consequently
are not consistently detected. A TG/total cholesterol ratio >5 (mg/
mg)> 2.2 (mmoL/mmoL) and a plasma apolipoprotein B concen-
tration <100mg/dL when plasma TG is> 10mmol/L strongly sup-
port the presence of a high amount of chylomicrons and very large
VLDL and remnants.
When the LPL activity assay can be performed (10min after IV
heparin injection [50 IU/kg]), LPL activity is found to be drastically
decreased in homozygous LPL FCS and often lowered in cases of
homozygous or compound heterozygous loss of function mutations
in APOC2, APOA5, GPIHBP1 and LMF1 (Table 1). Reproducible in-
creases of plasma TG> 10mmol/L (885mg/dL) over several weeks
or months is a relevant criterion supporting diagnosis of FCS.
Plasma TG levels in MCS have more variability and are much more
sensitive to dietary and/or ﬁbrate treatment, whereas in FCS, TG
concentration is minimally improved with these measures.
In addition to the lipid phenotype, some clinical features also
support the diagnosis of FCS, rather than the more common MCS.
FCS occurs in younger patients, mostly without secondary factors,
except for pregnancy and contraceptive oral oestrogen use,
whereas MCS typically occurs in overweight adult patients with
metabolic syndrome. Moreover, the occurrence of AP is more
frequent in FCS than in MCS due to the partial response to a low-fat
diet and higher plasma TG concentrations [38,39].
Next-generation sequencing is likely to facilitate the diagnosis
of FCS, since all the candidate genes can be tested in the same run.
However, due to its cost and paucity in core laboratories, not all
clinicians have access to genetic assessment.
We propose a pragmatic diagnostic score for FCS (Fig. 3), which
might help to distinguish between FCS and MCS, based on eight
biological/clinical items, including the history of plasma TG con-
centration, the lack of secondary factors (except for pregnancy and
oestrogenic oral contraceptives), history of AP, no history of familial
combined hyperlipidaemia [40] and age at the ﬁrst onset of
symptoms. A low weight was given to history of AP, since it is not
speciﬁc to FCS versusMCS, although it seems to bemore frequent in
FCS. In addition, a large proportion of young patients with FCS do
not yet have history of AP and would be excluded if the score gives
too much weight to this item.Table 1
Phenotypes in FCS.
LPL APOC2 APOA5
Transmission Recessive Recessive Co-dominant?
Variability of expressivity þ þþ þþþþ
Initiation Early Early Variable
Therapeutic resistance þþþ ± þþþ/þ
Relative frequency in FCS 35e50%a 5% 10%?
FCS, familial chylomicronemia syndrome; LPL, lipoprotein lipase; APOC2, apolipoprotein C
density lipoprotein-binding protein 1; LMF1, lipase maturation factor 1.
a Relative frequency may be high in an area with a strong founder effect.We initially tested the eight-item FCS score in two cohorts of 29
patients (see Methods in Ref. [41]). Sensitivity was estimated in an
FCS cohort and speciﬁcity was tested in an MCS cohort (Figs. 3, 4A
and B and Ref [41] Table 1).
The ability of the score to differentiate between FCS and MCS
patients was subsequently tested in two independent replication
Italian cohorts: the Rome Cohort (16 FCS and 15 MCS patients) and
the Palermo Cohort (eight FCS and eight MCS patients) (Fig. 4C and
D) [41]. The receiver operating characteristic (ROC) curve identiﬁed
the best cut-off corresponding to an FCS score of 10 (area under
the ROC curve 0.91). Within the FCS replication cohorts, sensitivity
(87.5%) was similar in the Palermo and Rome cohorts; however,
speciﬁcity tended to be lower in the Rome cohort than in the
Palermo cohort (87.5% vs 66.6%) (Fig. 5). Taking into account all the
patients studied, the overall sensitivity was 88% (95% conﬁdence
interval: 0.97, 0.76) with an overall speciﬁcity of 85% (95% conﬁ-
dence interval: 0.94, 0.75).
3.3. Discussion on diagnosis
A clinical diagnosis scoring system seems to be the best
approach to improve diagnosis of FCS. It would particularly facili-
tate the diagnosis of FCS in countries or areas where genetic testing
is unavailable despite its decreasing costs.GPIHBP1 LMF1 Anti-LPL/GPIHBP1 auto-antibodiesa
Recessive Recessive Sporadic
þþ þþþ Hectic
Variable Variable Adult
þþþ ? þþþ
5% 1% <1%
2; APOA5, apolipoprotein A5; GPIHBP1, glycosylphosphatidylinositol-anchored high-
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Fig. 4. Distribution of the FCS score in the different cohorts.
The dashed line corresponds to the cut-off set at 10. (A and B) The FCS score used for establishing the receiver operating characteristic curve. (C and D) The FCS scores in the
replication cohorts. FCS, familial chylomicronaemia syndrome; L, homozygous lipoprotein lipase; C, homozygous APOC2; G, homozygous GPIHBPI; G þ A5, heterozygous GPIHBPI-
APOA5; Het, heterozygous coding mutation; Pol, multiple functional SNPs.
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FCS diagnosis, it is sometimes difﬁcult to assess the functionality of
new variants. Conversely, in many patients with the FCS phenotype
(and no evidence for auto-antibodies against LPL, APOC2 or
GPIHBP1), a causative recessive loss of function mutation often
remains elusive [2,15]. Pragmatic clinical scoring is likely to be a
valuable phenotypic tool before performing next-generation
sequencing is widely available. In patients with FCS, setting a
lower cut-off than 10 would barely increase sensitivity in the two
FCS cohorts, since only three out of 53 FCS patients had a very low
score (FCS score 1 and 0), lower than most (83%) of the patients
with MCS (Fig. 4). This ﬁnding raises the question of unknown
factors involved in the highly variable expressivity of the disease,
such as additional genetic modulators.
The diagnostic performance of the score might be slightly lower
in non-homozygous LPL FCS patients due to a milder phenotype. In
addition, the sensitivity of the score might be mildly lower in Eu-
ropean patients with FCS than in Canadian LPL-deﬁcient patients.
This may be due to the more mixed genotype, consequent to a lack
of founder effect, and also to differences in nutrition and physical
activity, leading to lower plasma TG concentration for similar low
levels of LPL activity. This observation should be further tested inlarger international registries. The general applicability of this
scoring system in different geographical ancestries and ethnic
backgrounds needs additional studies.
The lower speciﬁcity in the Rome cohort is likely due to the
criteria used to enroll the Rome MCS cohort. In fact, these patients
were selected for having hyperchylomicronaemia without any
secondary factors; accordingly, most of them (73%) were hetero-
zygous for a coding mutation in one of the major genes involved in
plasma TG regulation. Conversely, the MCS cohort in Lyon included
all the consecutive MCS patients recruited for 2 years with a history
of severe HTG, and most of them (90%) had secondary factors.
Consequently, it is likely that 66% might be the lowest speciﬁcity in
severely hypertriglyceridaemic patients without any secondary
factors and that in the usual clinical setting, speciﬁcity would be
>80%, such as in Lyon and Palermo.
The setting of our pragmatic clinical score for this rare disease
was based on an initial cohort of 29 patients with an established
diagnosis of FCS, and the replication was tested in two smaller
cohorts of FCS patients from Italy (24 patients); these numbers are
rather large for such a rare disease. However, further validation in
additional larger cohorts of patients with FCS from various coun-
tries with a different spectrum of loss of function mutations will be
Cut-off ≥10 Palermo Replication Cohort (8 FCS, 8 MCS)
Cut-off ≥10 Rome Replication Cohort (16 FCS, 15 MCS)
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Fig. 5. Sensitivity and speciﬁcity of the FCS score.
Receiver operating characteristic curve of the FCS score. FCS, familial chylomicronae-
mia syndrome; MCS, multifactorial chylomicronaemia syndrome.
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and international registries, since it provides a way to take into
account the differences in expressivity of the disease [22,42].3.4. Treatment goals
The FCS score is a diagnostic tool. It should not be considered
conditional for new-generation treatments. The indication of such
treatments implies the assessment of the burden of the disease and
especially the risk of recurrent hypertriglyceridaemic pancreatitis.
The major aim of treatment for FCS is to reduce the risk of AP. Any
management strategy should always aim to prevent pancreatitis
events, which are characterised by marked increases in patient
morbidity andmortality in FCS. Despite the fact that not all patients
with HTG due to FCS develop pancreatitis, no biomarker is
currently available to predict the risk of developing pancreatitis.
Consequently, prevention of the occurrence of HTG remains the
only valid target to avoid new episodes of pancreatitis.
TG levels <10mmol/L (<885mg/dL) are the most appropriate
marker to reduce the risk of new episodes of AP. We suggest testing
at least four times per year directly following pancreatitis in un-
stable patients and at least twice a year in stable patients without a
history of HTG-induced pancreatitis. Bloodwithdrawal at the end of
the afternoon [43] in the post-prandial state may be an option to
challenge an apparently safe fasting plasma TG concentration. A
strict hypolipidic diet remains the cornerstone of treatment but is
often insufﬁcient to avoid decompensation and recurrences of AP
[2]. Since the majority of the TG-lowering interventions mediate
their effect at least partially via LPL-mediated TG clearance, routine
TG-lowering interventions are ineffective in FCS, including ﬁbrate
therapy and ﬁsh oil supplementation. Following the market with-
drawal of the LPL gene therapy alipogene tiparvovec, current
therapeutic options being investigated in FCS include apolipopro-
tein C3 antisense oligonucletotides (ASOs) [26,44] and
angiopoietin-like 3 ASOs or monoclonal antibodies [45e47].4. Data gaps
4.1. Areas requiring further attention
For patients with FCS, their symptoms, such as abdominal pain,
fatigue and the ability to engage in daily activities, disease com-
plications and adherence to a fat-restricted diet have an impact on
their quality of life [48]. In a recent web-based survey of 60 US
patients with FCS, a range of symptoms across the physical,
emotional and cognitive domains were found to contribute to the
burden of this illness [31]. More information is needed on how to
reduce the handicap on social, work and family life due to
abdominal pain, stress and strict diet restriction.
Since HTG has been found to correlate with decreased cognitive
function in some but not all epidemiological studies [49,50], eval-
uating cognitive function in FCS with appropriate tools such as the
Cambridge Neuropsychological Test Automated Battery could be
considered [51].
Further investigation of the relationship between diet and
pancreatitis is warranted. In addition to genetic factors, which need
to be further identiﬁed [52e55], dietary factors related to pancre-
atitis, beyond those strictly related to TG levels such as alcohol,
might be involved and could be a target. The mechanisms by which
high levels of chylomicrons increase the risk of pancreatitis are not
fully understood. Increased blood viscosity and impaired blood
ﬂow and peroxidative susceptibility causing pancreatic ischaemic
and oxidative injury have been proposed as key factors [56,57].
Better understanding of these processes might create some trans-
lational opportunities.
5. Conclusions
Improvement of diagnosis of FCS is an important challenge in
order to identify patients with the most severe form of HTG and
with the highest risk of AP. Due to the strong similarities of the
phenotype between FCS (considered as the recessive mono/bigenic
disorder) and MCS (oligo/polygenic), the FCS score presented here
provides a clinical tool able to discriminate between most cases. It
offers the opportunity to focus genetic assessment in a targeted
sub-population of hyperchylomicronaemic patients.
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